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Lung Function, Inﬂammation, and Endothelin-1 in Congenital Heart
Disease–Associated Pulmonary Arterial Hypertension
Andrew Low, MD, MRCP; Sarah George, PhD; Luke Howard, DPhil, FRCP; Nicholas Bell, BSc, FRCP; Ann Millar, PhD, FRCP;
Robert M. R. Tulloh, DM, FRCPCH
Background-—Breathlessness is the most common symptom in people with pulmonary arterial hypertension and congenital heart
disease (CHD-APAH), previously thought to be caused by worsening PAH, but perhaps also by inﬂammation and abnormalities of
lung function. We studied lung function and airway inﬂammation in patients with CHD-APAH and compared the results with controls.
Methods and Results-—Sixty people were recruited into the study: 20 CHD-APAH, 20 CHD controls, and 20 healthy controls.
Spirometry, gas transfer, whole body plethysmography and lung clearance index, 6-minute walk distance, and medical research
council dyspnea scoring were performed. Inﬂammatory markers and endothelin-1 levels were determined in blood and induced
sputum. The CHD-APAH group had abnormal lung function with lung restriction, airway obstruction, and ventilation heterogeneity.
Inverse correlations were shown for CHD-APAH between medical research council dyspnea score and percent predicted peak
expiratory ﬂow (r=0.5383, P=0.0174), percent predicted forced expiratory ﬂow rate at 50% of forced vital capacity (r=0.5316,
P=0.0192), as well as for percent predicted forced expiratory volume in 1 s (r=0.6662, P=0.0018) and percent predicted forced
vital capacity (r=0.5536, P=0.0186). The CHD-APAH patients were more breathless with lower 6-minute walk distance (360 m
versus 558 m versus 622 m, P=0.00001). Endothelin-1, interleukin (IL)-b, IL-6, IL-8, tumor necrosis factor a, and vascular
endothelial growth factor were signiﬁcantly higher in CHD-APAH than controls. Serum endothelin-1 for CHD-APAH correlated with
airﬂow obstruction with signiﬁcant negative correlations with percent predicted forced expiratory ﬂow rate at 75% of forced vital
capacity (r=0.5858, P=0.0135).
Conclusions-—Raised biomarkers for inﬂammation were found in CHD-APAH. Signiﬁcant abnormalities in airway physiology may
contribute to the dyspnea but are not driven by inﬂammation as assessed by circulating and sputum cytokines. A relationship
between increased serum endothelin-1 and airway dysfunction may relate to its bronchoconstrictive properties. ( J Am Heart
Assoc. 2018;7:e007249. DOI: 10.1161/JAHA.117.007249.)
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T he development of pulmonary arterial hypertension incongenital heart disease (CHD-APAH) is associated with
worsening exercise tolerance with breathlessness being the
most common symptom.1,2 Current drug therapies improve
exercise tolerance and reduce the perception of
breathlessness on exertion by decreasing pulmonary vascular
resistance and increasing cardiac output.3 However, patients
usually remain symptomatic despite medication and can
expect breathlessness to increase as their disease
progresses.3 The prognosis for patients with CHD-APAH is
better than for idiopathic PAH patients such that survival can
continue for many years, albeit with very limited exercise
activity.4
While abnormalities of pulmonary vasculature in CHD-
APAH have been well described,5 lung function abnormal-
ities are less clear, but could also contribute to symptoms.6
In idiopathic PAH, lung restriction and airﬂow obstruction
have been described.7–9 Some of these abnormalities
correlate with exertion dyspnea and reduction in exercise
tolerance.10,11 While some of these abnormalities have also
been described in CHD-APAH patients,9,12,13 a lack of
adequate controls makes the signiﬁcance unclear as
abnormal lung function has also been described in CHD
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patients without APAH.14 These might relate to coexisting
scoliosis or previous cardiothoracic surgery that is frequent
in this group and may be found in CHD patients both with
and without APAH.
We wished therefore to characterize the lung function
abnormalities in CHD-APAH and compare these with CHD
patients without APAH aswell as with healthy controls. We used
standard lung function measurements alongside the novel lung
clearance index (LCI), which has been shown to be a more
sensitivemeasure of airway obstruction than spirometry.15 This
study also aims to evaluate the potential role of inﬂammation
and endothelin-1 in airway dysfunction in CHD-APAH.
Inﬂammation plays a key role in a number of lung
conditions including asthma, chronic obstructive pulmonary
disease, and interstitial lung disease.16–18 Inﬂammation can
result in airﬂow obstruction through bronchoconstriction,
mucus plugging, lung tissue destruction, and airway
remodeling.18 In interstitial lung disease, the pattern of
chronic inﬂammation leads to tissue destruction and ﬁbrosis
resulting in lung restriction.17 It is not known whether such
patterns of lung inﬂammation occur in CHD-APAH, and there
are only limited reports of airway inﬂammation in other Group
1 PAH conditions.19
There is, however, growing evidence of a role for inﬂam-
mation in Group 1 PAH. Lung tissue biopsy samples of
patients with idiopathic pulmonary arterial hypertension
(IPAH) demonstrate perivascular inﬂammatory cell inﬁltrates
of T cells, B cells, and macrophages.20,21 Circulating levels of
serum cytokines including interleukin (IL)-1b, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12p70, and tumor necrosis factor a are
signiﬁcantly elevated when compared with controls.22,23 IPAH
shares a number of features with CHD-APAH,24 and inﬂam-
mation could develop in CHD-APAH because of the high
stresses associated with increased pulmonary blood ﬂow and
hypoxemia.25 Evidence of inﬂammation in CHD-APAH includes
inﬂammatory cell inﬁltrates around remodeled vessels,26,27
and elevated circulating levels of IL-6, tumor necrosis
factor a,.MCP-1, and C-reactive protein have also been
demonstrated.26–28
While there have been no studies to date looking at airway
inﬂammation or lung inﬂammation in CHD-APAH or IPAH,
given the proximity of these in the pulmonary vessels, a
spillover of such mediators could have effects within the
airways. Such protein movement from the systemic circula-
tion into the airways has been shown to occur, and this can
increase in the presence of inﬂammation caused by effects on
epithelial permeability.29,30 If an overspill of these inﬂamma-
tory mediators and cells into the airways occurs, the resulting
airway inﬂammation could account for the lung function
abnormalities seen, as can occur in other respiratory
conditions.16–18
Methods
Because of patient conﬁdentiality, the data, analytic methods,
and study materials will not be made available to other
researchers for purposes of reproducing the results or
replicating the procedure.
Patients with CHD-APAH were seen in the adult pulmonary
hypertension clinic and the data were stored in our hospital
database (HeartsuiteTM) at the Bristol Heart Institute. The clinic
is run as part of the UK National Pulmonary hypertension
service in conjunction with the Hammersmith Hospital.
Patients were invited to participate in our study between
2012 and 2014. Healthy controls and CHD controls without
APAH were recruited by internal advertisement in the hospital
and were not selected by the research team. All participants
provided informed consent and formal ethics approval was
obtained. In total, 20 CHD-APAH, 20 CHD controls, and 20
healthy controls were recruited.
Clinical Perspective
What Is New?
• Pulmonary arterial hypertension associated with congenital
heart disease is associated with restrictive lung function in
comparison with a control population of adults with
congenital heart disease who do not have pulmonary
arterial hypertension.
• Airways obstruction is associated with a raised level of
endothelin 1.
• Measurement of lung clearance index can demonstrate that
there is increased ventilator heterogeneity in this popula-
tion.
• Lung clearance index was a more sensitive measure of
airway obstruction than standard spirometry but not as
sensitive as midexpiratory ﬂows.
• Breathlessness in pulmonary arterial hypertension associ-
ated with congenital heart disease is associated with older
age, restrictive lung function, and raised endothelin 1.
• Airways inﬂammation is not seen in this population and not
associated with the systemic inﬂammation that is present.
What Are the Clinical Implications?
• Some of the breathlessness and exercise limitation might be
caused by airways disease, rather than pulmonary vascular
disease.
• As a result, there might be beneﬁt of therapy with
endothelin receptor antagonists, which will improve airways
mechanics. This effect might be in addition to that of
reducing pulmonary vascular resistance.
• There is no evidence from this study that the use of
inﬂammatory modulators would alter the airway mechanics
in this population.
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Exclusion criteria were any smoking history, Down syn-
drome or learning difﬁculties (because of compliance and
consent concerns), pre-existing lung disease, scoliosis, and
left heart dysfunction as assessed by echocardiography.
Healthy controls were also excluded if subsequent lung
function tests were abnormal with a forced expiratory volume
in 1 s (FEV1)/FVC ratio <70% or a TLC of <80% of predicted
values.
All participants performed routine spirometry, gas transfer,
and whole-body plethysmography in accordance with
guidelines.31 LCI was determined using a multiple-breath
washout technique with a modiﬁed Innocor device and 0.2%
SF6 as has previously been described.32 Six-minute walk test
was performed enabling maximum distance walked (6MWD),
minimum oxygen saturations, and maximum Borg score to be
determined.33 MRC dyspnea score and World Health Organi-
zation (WHO) performance status were also determined.34
Inﬂammatory cytokine and endothelin-1 levels were
determined from blood and induced sputum samples. All
measurements were obtained at a single visit.
Induced sputum was obtained as previously described.35
Dithiothreitol was used only after sputum supernatant was
removed as this has been reported to interfere with detection
of endothelin-1 and several other cytokines of interest.36
Subaliquots of supernatant were removed and stored at
70°C for later analysis.
Sputum was analyzed using trypan blue on a Neubauer
hemocytometer to determine the total cell count and using a
commercial modiﬁed Giemsa stain to determine the cell
differential.37 Twenty percent of slides were checked by an
independent pathologist to ensure accuracy.
IL-1b, IL-6, IL-8, IL-10, tumor necrosis factor a, and
vascular endothelial growth factor concentrations in sputum
and serum samples were determined using Luminex Perfor-
mance Assay (R&D Systems, Abingdon, UK) and read with a
Bio-Plex Magpix analyzer. Endothelin-1 levels were deter-
mined separately using a commercial ELISA kit according to
the manufacturer’s instructions (R&D Systems, Abingdon,
UK).
Statistical analyses were performed using Stata version
13.1. Comparison between groups was performed using 1-
way ANOVA (parametric data) with post hoc Bonferroni
analysis or Kruskal–Wallis (nonparametric data) with post
hoc analysis with Dunn’s correction where applicable for
multiple comparisons. Correlations were assessed using
the Spearman’s rank correlation coefﬁcient (for nonpara-
metric data). A P value of 0.05 or less was considered
signiﬁcant.
Ethical Approval
The study was sponsored by University Hospitals Bristol NHS
Foundation Trust—ME/2009/3142. Ethical approval was
granted by the South West Research Ethics Committee—
09/H0106/34.
Results
Sixty patients were recruited: 20 patients with CHD-APAH, 20
CHD, and 20 healthy controls. Standard lung function was
performed on all volunteers. Two healthy volunteers were
subsequently excluded, as their lung function (FEV1/FVC
ratio) was <70%. No healthy volunteers were excluded on the
grounds of low total lung capacity (TLC). The demographics of
the participants are summarized in Table 1.
There was a slight difference in age among the 3 groups
(P=0.0373 Kruskal–Wallis), with CHD-APAH patients slightly
older than healthy controls (42.7 years versus 31.6 years,
P=0.0226 Dunn’s), but not signiﬁcantly different from CHD
patients (40.0 years, P=0.9595 Dunn’s) and the median age
of CHD patients was not greater than that of healthy controls
(P=0.0725 Dunn’s). There was no statistically signiﬁcant
difference in the sex distribution among the 3 groups
(P=0.5266 v2). Height was not signiﬁcantly different in
CHD-APAH patients, CHD patients, and healthy controls
(166 cm versus 169 cm versus 173 cm), nor was body
weight (64.9 kg versus 72.4 kg versus 69.9 kg) (P=0.0826
Table 1. Patient Demographics for Patients With CHD-APAH, CHD Controls, and Healthy Volunteers
CHD-APAH (n=20) CHD (n=20) Healthy Volunteers (n=18) P Value*
Median age, y (IQR) 42.7 (33.1–57.7) 40.0 (32.8–50.6) 31.6 (25.6–38.4) 0.0373
Sex (M/F) 8/12 10/10 9/9 0.5266 (v2)
Median height, cm (IQR) 166 (157–172) 169 (164–180) 173 (168–178) 0.0868
Median weight, kg (IQR) 64.9 (56.4–77.2) 72.4 (64.0–81.4) 69.9 (58.6–85.0) 0.2575
Median BMI, kg/m2 (IQR) 23.3 (21.1–27.3) 24.3 (22.5–26.8) 22.5 (20.0–29.1) 0.6511
BMI indicates body mass index; CHD, congenital heart disease; CHD-APAH, congenital heart disease–associated pulmonary artery hypertension; F, female; IQR, interquartile range; M,
male.
*P values by Kruskal–Wallis unless otherwise stated, comparing 3 patient groups.
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and 0.2526 Kruskal–Wallis, respectively). There was also no
statistically signiﬁcant difference in body mass index (CHD-
APAH 23.3 kg/m2 versus CHD 24.3 kg/m2 versus healthy
controls 22.5 kg/m2, P=0.6511 Kruskal–Wallis).
As shown in Table 2, 11 of 20 patients with CHD-APAH
had Eisenmenger syndrome and 9 of 20 patients had APAH
following surgical operation.38 All the patients with Eisen-
menger syndrome had unrestrictive pulmonary outﬂow tracts
and hence had systemic level pulmonary artery pressures.
We do not undertake cardiac catheterization in these
patients and therefore have not measured their pulmonary
artery pressure directly. The pressures in those patients who
had had an operation were either late shunt repairs (the
case with atrial septal defect), or had signiﬁcant residual
ventricular septal defect (VSD) (in both those with VSD) that
had not been closed. All had undergone cardiac catheter-
ization and the pressures were either systemic or were as
described in Table 3. The 3 patients with transposition of
the great arteries had had atrial switches and had been fully
assessed to ensure there was no evidence of venous
pathway obstruction, tricuspid regurgitation, or right ventri-
cle dysfunction. The pulmonary artery pressures were
assessed from cardiac catheterization in each case and
the pulmonary capillary wedge pressure conﬁrmed the
absence of pulmonary venous hypertension. They are
classiﬁed according to the system proposed by Galie et al.34
There were no patients with CHD-APAH with a predominant
systemic-to-pulmonary shunt, or with a small coincidental
lesion. The most common congenital heart defect in the
CHD-APAH patient group was a VSD that affected 10 of the
20 patients. Two patients had had an atrial septal defect,
and 8 of 20 CHD-APAH patients had complex congenital
heart disease, including transposition of the great arteries,
double inlet left ventricle and tricuspid atresia. CHD controls
included patients with small atrial septal defect, VSD, and
transposition of the great arteries, as well as patients with
tetralogy of Fallot, pulmonary stenosis, Ebstein anomaly, and
1 patient with truncus arteriosus. None of the patients had
learning difﬁculties or 22q11 microdeletion.
In all patients, echocardiography was undertaken before
entry to the study. All the CHD patients and controls were
conﬁrmed to have good systemic systolic ventricle function
(fractional shortening, S’, tricuspid annular plane excursion
(TAPSE), mitral annular plane excursion (MAPSE) as appropri-
ate), no or insigniﬁcant systemic atrioventricular valve regur-
gitation and no diastolic dysfunction as judged by inﬂow
Table 2. Clinical Classiﬁcation and Lesion Type for Patients With CHD-APAH and CHD Controls38
Eisenmenger PAH With Systemic-Pulmonary Shunt PAH With Small Defect PAH After Surgical Operation CHD Controls Without APAH
ASD 1   1 2
VSD 8   2 3
TGA    3 5
DILV 2   1 
Tricuspid atresia    2 
Tetralogy of Fallot     3
Pulmonary stenosis     4
Truncus arteriosus     1
Ebstein anomaly     2
ASD indicates atrial septal defect; CHD-APAH, congenital heart disease–associated pulmonary artery hypertension; DILV, double inlet left ventricle; TGA, transposition of the great arteries;
VSD, ventricular septal defect.
Table 3. Hemodynamics for Patients With CHD-APAH
Eisenmenger PA Pressure PAH After Surgical Operation Mean PA Pressure, mm Hg SvO2, % RAp, mm Hg
ASD 1 Systemic 1 62 73 11
VSD 8 Systemic 2 93, 104 56, 61 8, 6
TGA   3 73, 58, 95 55, 71, 66 13, 12, 14
DILV 2 Systemic
Tricuspid atresia   2 (Fontan) 14, 17
Both of the patients with Fontan procedure had transpulmonary gradient >8 mm Hg. ASD indicates atrial septal defect; CHD-APAH, congenital heart disease–associated pulmonary artery
hypertension; DILV, double inlet left ventricle; PA, pulmonary artery; RAp, right atrial pressure; SvO2, mixed venous oxygen saturations; TGA, transposition of the great arteries; VSD,
ventricular septal defect.
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Doppler interrogation. There was no evidence of branch
pulmonary artery obstruction or other hemodynamic concern
that would have altered the interpretation of the data.
Seventeen of 20 CHD control patients had undergone
previous sternotomy with none having a prior thoracotomy.
The remaining 3 CHD patients included 2 patients with a
nonsurgical Amplatzer device closure of atrial septal defect
and 1 patient with a small VSD. The 10 CHD-APAH patients
with previous surgery included 6 with prior sternotomy and 4
who had had both a sternotomy and a thoracotomy. No
healthy controls had prior cardiothoracic surgery.
The lung function for the 3 groups was as shown in
Table 4. These data demonstrate that lung function in
patients with CHD-APAH is abnormal in comparison to CHD
patients without associated PAH and also in comparison to
healthy controls. Lung volumes including TLC and FVC were
reduced in CHD-APAH in keeping with lung restriction, while
residual volume was relatively increased in comparison to
TLC, demonstrating relative hyperinﬂation in these patients.
This may be because of gas trapping resulting from airway
obstruction that was demonstrated by reductions in FEV1/
FVC ratio and reduced midexpiratory ﬂows. This is further
supported by LCI measurements that were abnormally high in
CHD-APAH patients and normal in CHD and healthy controls.
Gas transfer measurements were also abnormal in both CHD-
APAH patients and CHD patients in comparison to healthy
controls, but when accounting for transfer coefﬁcient (KCO),
there was no signiﬁcant difference between CHD patients
with and without APAH.
As shown in Table 5, patients with CHD-APAH were more
functionally limited as determined by both 6MWD and WHO-
Functional Class (FC) and more breathless on MRC dyspnea
score and by Borg score during the 6-minute walk test.
Lung function and its association with breathlessness and
exercise tolerance in CHD-APAH patients were assessed. A
weak but signiﬁcant correlation was shown between percent
predicted TLC and 6MWD (r2=0.2306, P=0.0043) and
between percent predicted FVC and 6MWD (r2=0.3347,
P=0.0095), while an inverse correlation was found between
residual volume/TLC ratio and 6MWD for these patients
(r2=0.3227, P=0.0139). Signiﬁcant negative correlations were
also shown for CHD-APAH between MRC dyspnea score and
percent predicted peak expiratory ﬂow rate (r=0.5383,
P=0.0174), percent predicted FEF50 (r=0.5316, P=0.0192),
percent predicted FEF75 (r=0.5927, P=0.0075), and per-
cent predicted FEF25-75 (r=0.5536, P=0.0139) as well as
for percent predicted FEV1 (r=0.6662, P=0.0018) and
percent predicted FVC (r=0.5536, P=0.0186), and a positive
correlation for percent predicted residual volume/TLC ratio
(r=0.573, P=0.0129). There was a signiﬁcant correlation
between age and LCI in CHD-APAH patients. Multiple
regression was therefore performed, and this demonstrated
that LCI is signiﬁcantly determined by presence of APAH
(P=0.041) and age (P<0.0001) but CHD-APAH type did not
Table 4. Lung Function by Patient Group
CHD-APAH CHD Healthy Volunteers P Value*
Total number 20 20 18
TLC 80.0 (77.2–98.0) 96.3 (86.3–104.6) 94.2 (87.0–100.2) 0.0344/0.027/0.046
FVC 77.8 (73.9–100.0) 101.8 (90.8–122.2) 106.1 (96.0–109.5) 0.0005/0.0011/0.0012
RV 88.8 (68.8–124.6) 84.0 (76.9–87.7) 79.9 (73.8–92.9) 0.4197 (not significant)
RV/TLC 110.7 (93.6–137.4) 85.4 (72.8–94.2) 83.2 (71.1–90.6) 0.0004/0.0006/0.0018
FEV1 70.7 (58.5–81.8) 95.1 (90.4–112.1) 99.1 (92.9–105.0) 0.0001/<0.0001/<0.0001
FEV1/FVC Ratio 0.719 (0.680–0.778) 0.790 (0.768–0.818) 0.815 (0.769–0.869) 0.0021/0.0272/0.0009
PEFR 83.7 (65.9–99.9) 111.0 (88.8–119.6) 101.5 (90.7–115.0) 0.0019/0.0014/0.0096
FEF25 72.1 (63.2–92.5) 106.7 (76.8–128.7) 102.3 (86.6–109.4) 0.0006/0.0007/0.0027
FEF50 44.0 (28.8–63.6) 82.3 (61.3–103.0) 85.9 (70.4–94.0) 0.0001/0.0001/<0.0001
FEF75 29.8 (22.0–39.0) 61.4 (44.9–78.3) 78.6 (57.3–97.4) 0.0001/0.0001/<0.0001
FEF25-75 39.6 (27.1–53.5) 76.3 (61.0–101.2) 79.0 (70.0–97.1) 0.0001/<0.0001/<0.0001
TLCO 64.5 (53.4–74.4) 89.0 (79.5–100.8) 95.0 (84.6–104.0) 0.0001/0.0001/<0.0001
KCO 84.2 (74.6–94.3) 89.7 (81.9–100) 97.2 (86.4–114.8) 0.0073/0.11/0.0027
LCI 7.6 (6.99–9.70) 6.77 (6.56–7.32) 6.41 (6.14–7.15) 0.0004/0.0098/0.00024
For patients with congenital heart disease–associated pulmonary artery hypertension (CHD-APAH), CHD controls, and healthy volunteers. Data expressed as median percentage predicted
(interquartile range). FEF 25/50/75 indicates forced expiratory ﬂow at 25/50/75% of FVC; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; KCO, transfer
coefﬁcient; LCI, lung clearance index; PEFR, peak expiratory ﬂow rate; RV, residual volume; TLC, total lung capacity; TLCO, transfer factor for carbon monoxide.
*P value: Kruskal–Wallis, and where P<0.05, the following P values are for CHD-APAH vs CHD and then CHD-APAH vs healthy controls by post hoc Dunn’s correction.
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reach statistical signiﬁcance (P=0.118). On univariant analy-
sis, there was also no correlation between LCI and body mass
index, sex, or type of surgery (thoracotomy or sternotomy).
Figure 1 demonstrates that there were signiﬁcant differ-
ences in serum cytokines levels among the 3 groups, with IL-
b, IL-6, IL-8, and vascular endothelial growth factor levels all
signiﬁcantly higher in CHD-APAH patients than in CHD or
healthy controls. Tumor necrosis factor a levels were also
greater in CHD-APAH patients compared with healthy controls
but with no signiﬁcant difference in comparison to CHD
controls. There were no differences found in serum IL-10
levels across the 3 groups. Serum endothelin-1 levels were
also signiﬁcantly higher in CHD-APAH patients.
When sputum samples were analyzed for cell count, no
differences were found among the groups (Table 6). There
was also no difference in the cytokine levels in sputum, in
contrast to the ﬁndings in serum (Figure 2).
Serum endothelin-1 levels for CHD-APAH patients corre-
lated with measures of airﬂow obstruction with signiﬁcant
negative correlations with percent predicted FEF25-75
(r=5417, P=0.0247 Spearman) and percent predicted
FEF75 (r=0.5858, P=0.0135). There were no signiﬁcant
correlations between serum endothelin-1 levels and FEV1/
FVC ratio (r=0.2770, P=0.2818 Spearman) or LCI
(r=0.2170, P=0.4027 Spearman). There were no signiﬁcant
correlations between measures of airﬂow obstruction and
serum endothelin-1 for CHD and healthy controls. Linear
regressions are displayed in Figure 3 showing the endothelin
level correlation with restrictive lung function and with LCI.
Discussion
Breathlessness is the most common symptom experienced
by patients with CHD-APAH. It is the presenting symptom in
up to 70% of patients and affects almost all with advanced
disease.39,40 While breathlessness in CHD-APAH patients
has been attributed to abnormal pulmonary hemodynamics
and reduced cardiac output, this study demonstrates that
these patients also have abnormal lung function in compar-
ison to both healthy controls and CHD patients without
APAH. These abnormalities include lung restriction with
reduced TLC and FVC, and airway obstruction with reduc-
tions in FEV1/FVC ratio, midexpiratory ﬂows, and increased
LCI compared with CHD and healthy controls. It was also
demonstrated that both CHD-APAH and CHD patients had
reduced gas transfer measurements in comparison to
healthy controls.
Reductions in TLC and FVC described in the present study
were in keeping with other studies that have also described
lung restriction.12,13,41 However, these studies lacked CHD
controls for comparison. The ﬁndings of the present study,
however, are in conﬂict with a study that demonstrated that
Eisenmenger patients have near normal lung volumes, but
that study had no controls—either healthy or CHD patients
without PAH.42 In addition, unselected CHD patients have
been reported as having reduced FVC, which may be related
to features such as scoliosis (which was excluded from the
present study) and previous cardiothoracic surgery.14,43 The
present study demonstrates that lung restriction occurs in
CHD-APAH compared with CHD and healthy controls without
scoliosis. While thoracotomy was associated with lung
restriction, sternotomy was not, which is in keeping with
previous studies.14 However, patients who had not had
previous cardiothoracic surgery also had lower lung volumes
than predicted values, suggesting that the presence of APAH
may have a separate effect on lung restriction in keeping with
lung restriction that has been described in IPAH
patients.8,9,13,44,45
Table 5. Breathlessness and Exercise Tolerance by Group
CHD-APAH CHD Healthy Volunteers P Value
Total number 20 20 18
WHO-FC (I/II/III/IV) 2/8/10/0 13/7/0/0 18/0/0/0 0.000
Fisher exact
WHO, median 2.5 (2–3) 1 (1–2) 1 (1–1) 0.0001
MRC dyspnea score (1/2/3/4/5) 2/8/9/1/0 13/7/0/0/0 18/0/0/0/0 0.0001
Fisher exact
MRC, median 2.5 (2–3) 1 (1–2) 1 (1–1) 0.0001
Saturation % at rest 82 (72–89) 94 (82–96) 97 (94–99) 0.0001
Saturation % at end 6MWD 68 (45–82) 89 (69–96) 96 (94–98) 0.0001
Mean 6MWD, m (SD) 360.35 (123.01) 558.82 (70.59) 622.0 (80.40) 0.00001
ANOVA
For patients with congenital heart disease–associated pulmonary artery hypertension (CHD-APAH), CHD controls, and healthy volunteers. Kruskal–Wallis for nonparametric data, ANOVA
for parametric data, v2 for proportions, and Fisher exact for proportions where >20% of cells have expected frequencies of <5. 6MWD indicates 6-minute walk distance; MRC, medical
research council; WHO-FC, World Health Organization Functional Class.
DOI: 10.1161/JAHA.117.007249 Journal of the American Heart Association 6
Lung Function and Inﬂammation in CHD-APAH Low et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 23, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
All measurements of airﬂow were reduced in CHD-APAH
patients including FEV1/FVC ratio, FEV1, peak expiratory
ﬂow rate, FEF25, FEF50, FEF75, and FEF25-75, indicating
the presence of airway obstruction. While this has been
suggested by previous studies, such studies have lacked
adequate controls for comparison.9,41,42 The FEV1/FVC
ratio was >70% in this present study and could be
interpreted as an absence of airway obstruction in keeping
with other reports; however, this would be an over-
simpliﬁcation.12,13 This study conﬁrms that the FEV1/FVC
ratio is signiﬁcantly reduced in comparison to both control
groups, and in addition all other markers of airway
obstruction were signiﬁcantly less. This therefore conﬁrms
that airway obstruction is found in CHD-APAH patients
Figure 1. Serum cytokines (pg/mL) by group. Data displayed as box and whisker plots of median,
interquartile range, and minimum and maximum values. For cytokine concentrations with a statistically
signiﬁcant difference between groups (P<0.05 Kruskal–Wallis), the P value is indicated (Dunn’s). A, IL-1b
(P=0.0214 Kruskal–Wallis), (B) IL-6 (P=0.0005 Kruskal–Wallis), (C) IL-8 (P=0.0161 Kruskal–Wallis), (D) IL-10
(P=0.1119 Kruskal–Wallis), (E) TNFa (P=0.0411 Kruskal–Wallis), (F) VEGF (P=0.0232 Kruskal–Wallis) and
(G) endothelin-1 (P=0.0001 Kruskal–Wallis). IL indicates interleukin; TNFa, tumor necrosis factor a; VEGF,
vascular endothelial growth factor.
Table 6. Total Cell Count for Induced Sputum Samples for Patients With CHD-APAH, CHD Controls, and Healthy Volunteers
CHD-APAH (n=10) CHD (n=10) Healthy Control (n=10) P Value
Total cell count, mean 9106/g (SD) 1.96 (1.44) 1.51 (0.84) 2.58 (1.41) 0.19
Cell differential count, mean % (SD)
Macrophages 52.1 (28.2) 53.2 (16.1) 53.3 (31.3) 0.9942
Neutrophils 46.7 (28.3) 44.0 (15.2) 45.4 (30.9) 0.9737
Eosinophils 0.3 (0.37) 1.2 (1.8) 1.0 (1.4) 0.3509
Lymphocytes 0.9 (1.1) 1.6 (2.7) 0.3 (0.4) 0.2512
Cell differential percentages for induced sputum samples. Data are displayed as mean % (SD). P values ANOVA. CHD-APAH indicates congenital heart disease–associated pulmonary artery
hypertension;
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compared with both healthy controls and CHD controls
without APAH.
LCI in CHD-APAH has not been previously described, but
the elevation further supports the presence of airway
obstruction in CHD-APAH. This is a measurement of ventila-
tion heterogeneity that has been shown in cystic ﬁbrosis to be
a more sensitive measure of airway obstruction than
spirometry.15 Although more sensitive than routine spirometry,
it was not as sensitive as midexpiratory ﬂow measures such
as FEF25-75 and FEF75. However, the clinical utility of
midexpiratory ﬂows is limited by its reproducibility and lack of
agreed limits of normality.46 LCI may therefore be a useful
adjunct, which has a clear abnormal upper limit and thus is
much more straightforward to interpret.15 In addition, use of
LCI may also have a role in obtaining lung function measures
in CHD-APAH patients with learning difﬁculties, which are
common in this patient group and where reliable measures of
lung function are difﬁcult to obtain.47 For LCI, patients are
required to breathe through a mouthpiece with normal tidal
breathing throughout, without the need for any complex
maneuvers.
Airway obstruction would account for gas trapping demon-
strated by the raised residual volume/TLC ratio found. This is
in keeping with studies in which a raised residual volume/TLC
ratio has been described in both CHD-APAH patients42 and
IPAH patients.7 The degree of gas trapping may be related to
the severity of pulmonary vascular disease in IPAH, and may
therefore result in an increase in TLC in more advanced
disease. This could also explain some of the conﬂicting
reports regarding lung volumes in CHD-APAH.12,13,41,42
Gas transfer measurements for CHD-APAH patients were
reduced as in previous studies.9,13,41,42 We showed a
signiﬁcant difference in TLCO between CHD patients with
and without APAH, but no signiﬁcant difference was demon-
strated in TLCO or KCO between CHD patients without APAH
and healthy controls. Potential causes for abnormal gas
transfer measure in CHD-APAH patients include reduced
pulmonary capillary blood volume and pulmonary membrane
diffusion capacity as a consequence of increased pulmonary
vascular resistance, reduced cardiac output, and endothelial
cell proliferation. While pulmonary edema could affect gas
transfer measurements through widening of the alveolar-
Figure 2. Induced sputum cytokines by group. Data displayed as box and whisker plots demonstrating
median, interquartile range, and minimum and maximum values. A, IL-1b (P=0.2126 Kruskal–Wallis), (B) IL-6
(P=0.7159 Kruskal–Wallis), (C) IL-8 (P=0.9351 Kruskal–Wallis), (D) IL-10 (P=0.5719 Kruskal–Wallis), (E)
TNFa (P=0.5719 Kruskal–Wallis), (F) VEGF (P=0.9645 Kruskal–Wallis), and (G) endothelin-1 (P=0.1810
Kruskal–Wallis). CHD-APAH indicates congenital heart disease–associated pulmonary artery hypertension;
IL, interleukin; TNF Alpha, tumor necrosis factor a; VEGF, vascular endothelial growth factor.
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capillary membrane, patients with left heart dysfunction on
echocardiogram were excluded from this study and therefore
would not explain the results of this present study.
It is of note that there were 2 patients with Fontan
procedures in our study population. There is much discussion
about the deﬁnition of pulmonary hypertension, but both
patients had transpulmonary gradients of >8 mm Hg and thus
would seem reasonable to include in a study on pulmonary
vascular disease. Neither patient had impaired systemic
ventricular function, or systemic atrioventricular valve regur-
gitation, so it must be presumed that there was increased
pulmonary vascular stiffness if not pulmonary arterial hyper-
tension by the formal deﬁnition.
CHD-APAH patients were more breathless with higher MRC
dyspnea scores and higher Borg scores during the 6-minute
walk test, and these patients were conﬁrmed to be more
functionally limited with higher WHO-FC and reduced
6MWD.48 This present study demonstrates that lung restric-
tion correlates with 6MWD and Borg score during the 6-
minute walk test, which is in conﬂict with a previous study
that did not demonstrate such a relationship.42 However, as
discussed previously, this prior study did not ﬁnd any
reduction in lung volumes, which would account for this lack
of association described. However, our study did not ﬁnd a
correlation between lung volumes and MRC dyspnea score or
WHO-FC. FEV1/FVC ratio was not associated with any
measures of breathlessness or exercise tolerance. While LCI
was shown to be a more sensitive measure of airway
obstruction than spirometry, this also failed to demonstrate
any signiﬁcant correlation with symptoms or functional
limitation. FEF25-75 and FEF75 were more sensitive than
both FEV1/FVC ratio and LCI, and correlated with MRC
dyspnea scores and WHO-FC, but there were no signiﬁcant
associations with 6MWD or Borg score. No signiﬁcant
Figure 3. Serum endothelin-1 and lung function. A, FEV1/FVC ratio. Linear regression for CHD-APAH
r2=0.2032, P=0.0693 (red dotted line) and CHD and healthy controls combined r2=0.0054, P=0.6714 (blue
dotted line); (B) Percent predicted FEF25-75. Linear regression for CHD-APAH r2=0.3733, P=0.0092 (red
dotted line) and CHD and healthy controls combined r2=0.0000, P=0.9912 (blue dotted line); (C) Percent
predicted FEF75. Linear regression for CHD-APAH r2=0.3500, P=0.0124 (red dotted line) and CHD and
healthy controls combined r2=0.0008, P=0.8733 (blue dotted line); (D) Lung clearance index. Linear
regression for CHD-APAH r2=0.2307, P=0.0510 (red dotted line) and CHD and healthy controls combined
r2=0.0308, P=0.3062 (blue dotted line). CHD-APAH indicates congenital heart disease–associated
pulmonary artery hypertension; FEF 25/50/75, forced expiratory ﬂow at 25/50/75% of FVC; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity.
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relationship between KCO and measures of breathlessness of
functional limitation were demonstrated. While lung restric-
tion appeared to be related to some symptom and exercise
tolerance measures, this could reﬂect a relationship with
previous thoracotomy or more complex CHD rather than
reﬂecting an association between APAH and lung volumes.
It may also be possible that the measures of breathless-
ness and exercise tolerance were not sensitive enough to
demonstrate such a relationship. The WHO-FC and MRC
dyspnea score are 4- and 5-point scales, respectively, and
while the Borg score has a wider 10-point scale, this was used
to measure breathlessness in response to a speciﬁc task
rather than an assessment of symptoms during usual
activities. The use of cardiopulmonary exercise testing, which
is a maximal exercise test, may have achieved a clearer
relationship with lung function abnormalities. Lung function
abnormalities could be an innocent bystander, a result of
another problem, outweighed by abnormalities in pulmonary
vasculature and cardiac output. A larger study would be
required to investigate this area further.
It is known that patients with CHD-APAH have evidence of
systemic inﬂammation,26–28 and elevated serum endothelin-1
levels.49 While airway inﬂammation plays a key role in a
number of respiratory diseases such as asthma, chronic
obstructive pulmonary disease, and interstitial lung
disease,16–18 endothelin-1 can cause potent bronchoconstric-
tion in vitro,50 and has been found in elevated levels in
induced sputum and bronchoalveolar lavage samples in cystic
ﬁbrosis and chronic obstructive pulmonary disease,51,52 but
airway inﬂammation has not been studied in the present
group. It is thus possible that inﬂammation and endothelin-1
could play a role in the pathogenesis of lung function
abnormalities demonstrated in this patient group. This
present study demonstrated evidence of systemic inﬂamma-
tion in keeping with these previous studies, but this was not
conﬁrmed in induced sputum across the 3 patient groups.
While it is recognized that a limited number of inﬂammatory
cytokines were assessed, the ﬁndings of this study do not
support a role of inﬂammation in the pathophysiology of
abnormal lung function in CHD-APAH.
Endothelin-1 is a vasoconstrictor that is found in elevated
levels in CHD-APAH and contributes to the development of
PAH49 and is a potent bronchoconstrictor. Thus, it was
hypothesized that endothelin-1 could play a key role in airway
obstruction in CHD-APAH patients.50 Serum endothelin-1
levels were increased in CHD-APAH patients in comparison to
CHD and healthy controls in keeping with other studies. While
induced sputum levels were not elevated in CHD-APAH
patients, it was shown that endothelin-1 levels correlated with
measures of airway obstruction in CHD-APAH. While a
proposed role for endothelin-1 in airway obstruction in CHD-
APAH has biological plausibility, a key limitation is that
causation was not shown and would require further
investigation.
Conclusion
Lung function is abnormal in CHD-APAH with evidence of lung
restriction and airway obstruction in comparison to CHD and
healthy controls. Evidence of airway obstruction was also
supported by the demonstration of increased ventilation
heterogeneity with abnormally elevated LCI in this patient
group. Lung restriction may in part be caused by previous
cardiothoracic surgery, while airway obstruction may be
related to elevated serum endothelin-1 levels. While systemic
inﬂammation is present in these patients, airway inﬂammation
was not demonstrated and was not shown to be associated
with airway obstruction. LCI was a more sensitive measure of
airway obstruction than standard spirometry, but not as
sensitive as midexpiratory ﬂows. LCI may be a more
reproducible measure than midexpiratory ﬂows and may be
easier to perform in patients with learning disabilities, which
are a large cohort of CHD-APAH patients, though this requires
further investigation. Correlations between these lung func-
tion abnormalities, breathlessness, and exercise limitation
were demonstrated, which may indicate they contribute to
patients’ symptoms. However, further work is required in this
area to elucidate the pathophysiology of these abnormalities
and determine whether treatment may beneﬁt CHD-APAH
patients.
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